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Glucocorticoids (GCs) are hormones released during the stress response that are well known for their immu-
nosuppressive and anti-inflammatory properties; however, recent advances have uncovered situations
wherein they have effects in the opposite direction. The CNS is a particularly interesting example, both
because of its unique immune environment, and because GCs affect immune responses differently in
different brain regions. In this minireview we discuss the contexts wherein GCs increase CNS inflammation
and point out directions for future investigation.We are born with the ability to respond to stress, and this is fortu-
itous because the act of being born is the first of many stressors
that we will experience. As anyone who has come down with
a cold during a stressful period knows, stress can impair immune
function. In this minireview we review recent advances and
remaining gaps in our understanding of how stress hormones
affect inflammation, with a particular focus on the CNS. As the
key point, a class of stress hormones renowned for their capacity
to suppress inflammation often fails to do so, and can even
worsen inflammation in the injured CNS.
An Introduction to Glucocorticoids
and the Stress Response
Our understanding of the stress response aptly began during the
American Great Depression. In 1935, Walter Cannon described
the extraordinary flexibility of the body in its ability to respond
to stress, or ‘‘accidents of existence’’ (Cannon, 1935). Cannon
called the stress-induced increases in cardiac output the ‘‘fight
or flight’’ response, and he had realized the importance of
adrenal hormones in this response as early as 1924. In 1936,
Hans Selye described the ‘‘general adaptation syndrome,’’ acti-
vated by an organism in order to overcome various challenges.
The first observation that the stress response might have effects
on immunity came when Selye noted that chronic stress atro-
phied the thymus (Selye, 1936).
The canonical physiological stress response begins when the
brain detects a homeostatic challenge and activates the sympa-
thetic nervous system (SNS), which releases the catecholamines
epinephrine (E) and norepinephrine (NE). This is followed by the
slower activation of the hypothalamic-pituitary-adrenal (HPA)-
axis: hypothalamic secretion of corticotropin-releasing hormone
(CRH) into the pituitary portal circulation triggers pituitary secre-
tion of adrenocorticotropic hormone (ACTH), which then stimu-
lates the secretion of glucocorticoids (GCs) by the adrenals
(the endogenous GC is cortisol in primates and corticosterone
in most rodents, hereafter abbreviated as CORT). While this
review focuses on GCs, a number of other stress-responsivehormones affect immune function, so the effects of GCs are
not always identical to the effects of stress. Moreover, the func-
tioning of the HPA axis, and, indeed, all the facets of the stress
response, show tremendous individual variability, a fact that
helps to explain the considerable individual differences in vulner-
ability to stress-related disease (including psychiatric disorders).
Across all species, CORT secretion into the bloodstream
peaks just prior to waking, with a 5-fold variation in levels across
the circadian cycle. In response to substantial stressors, CORT
secretion increases approximately an order of magnitude. In
the literature, the type and duration of stressor used varies
considerably. In this perspective, we define ‘‘acute stress’’ as
a stressor of a few hours. If such stress is repeated daily for
several days we will refer to it as ‘‘subacute stress,’’ and if it
persists for weeks to months, then it is termed ‘‘chronic stress.’’
Once secreted, CORT is regulated at many stages before
binding to a receptor in a target cell (Figure 1). Beginning in the
bloodstream, CORT is normally 90% bound to corticosterone-
binding globulin (CBG), and only unbound CORT readily crosses
the blood-brain barrier (BBB) and cell membranes. Once in the
cytoplasm, it can bind to two different receptors, the mineralocor-
ticoid receptor (MR) or the glucocorticoid receptor (GR). When
unoccupied, these receptors are bound to heat shock proteins
(HSPs). On binding CORT, they homodimerize, shed their HSP
chaperones, and translocate to the nucleus where they regulate
gene transcription. The affinity of CORT for MR is10-fold higher
than for GR, with MR heavily occupied by basal CORT levels and
GR only heavily occupied during moderate to severe stress.
Because MR and GR signaling can have different transcriptional
effects, basal and high-stress CORT levels can have divergent,
even opposite effects. In combination, this can produce an
‘‘inverse-U’’ pattern, where basal CORT levels produce a partic-
ular effect (mediated by heavy MR occupancy), and where the
opposite effect occurs with either below normal (and insufficient
MR occupancy) or elevated CORT levels (and heavy GR occu-
pancy). This is often observed in the nervous system. For
example, while basal to low stress levels of CORT enhanceNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 33
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MinireviewFigure 1. Multiple Levels of GC Signaling
and Regulation
Blood: Beginning in the bloodstream, approxi-
mately 90% of CORT is bound to CBG, whereas
DEX and predisone do not bind CBG. BBB: Only
unbound CORT is able to cross the BBB. DEX
and prednisone are both extruded by the multi-
drug resistance transporters. Cytoplasm: Once
CORT has entered the cell, it can bind to MR,
GR, or both, or it can be degraded by the enzyme
11b-HSD. Nucleus: Both GR and MR are normally
bound to HSPs and other cofactors in the cyto-
plasm. On binding GCs they undergo a conforma-
tional change that releases these HSPs. Activated
receptors then homodimerize and enter the
nucleus where they mediate changes in gene tran-
scription either via binding to GC response
elements upstream of target genes or physically
interacting with other transcription factors (e.g.,
NF-kB).cerebral perfusion rate, glucose utilization, hippocampal syn-
aptic excitability, and hippocampal-dependent learning, higher
physiological levels of CORT do the opposite in all of these realms
(Sapolsky, 2004). These complexities and MR and GR function
are also pertinent to understanding GC effects in the immune
system. For example, different immune cell populations and
tissues express these two receptors heterogeneously and will
thus respond differently to CORT (McEwen et al., 1997).
It has become clear that steroid hormones can have rapid
effects that are independent of classical transcription-depen-
dent receptor signaling, implying that GCs are interacting with
other proteins, receptors, or membrane channels. For CORT,
these effects are important in the control of motor activity,
memory, and HPA regulation (Dallman, 2005). There is some
evidence that membrane-bound MR is responsible for some of
these fast-acting CORT effects (Karst et al., 2005).
Synthetic versions of CORT (e.g., prednisone and dexametha-
sone [DEX]) were created to harness its immunosuppressive prop-
erties. The distinction between synthetic GCs and CORT is critical
because they have different receptor binding affinities (e.g., DEX
is a selective GR agonist in vivo). Furthermore, synthetic GCs do
not bind CBG, and thus have much stronger effects than CORT
(McEwen et al., 1997). In the CNS the picture is more complex
because synthetic GCs are excluded from crossing the BBB by
multidrug resistance transporters (De Kloet et al., 1998). Thus,
in vivo studies using synthetic GCs must utilize high enough doses
to overwhelm these transporters if central effects are desired.
The 1950 Nobel Prize was awarded for identifying the anti-
inflammatory properties of GCs; in this perspective we trace
how this view has been refined in the decades since. In the last
decade, increasingly reductive studies have revealed situations
where GCs actually increase inflammation, including in the
injured CNS. Because of the obvious clinical implications of these
findings, it is imperative to determine how GCs affect CNS inflam-
mation, particularly when they make it worse. We begin with the
well-studied anti-inflammatory effects of GCs as a prelude to
considering the situations where GCs make inflammation worse.
When GCs Are Immunosuppressive
We begin outside the CNS, where the anti-inflammatory proper-
ties of GCs have been most studied (for more detail, see De34 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.Bosscher et al., 2003). The context of GC exposure is critical in
determining how GCs will affect inflammation. Important details
to consider include (1) whether the duration of exposure is acute,
subacute, or chronic; (2) whether GC levels are basal, in the
stress range, or supraphysiological; (3) the timing of GC expo-
sure relative to immune activation; and (4) which type of GC is
used. Additional relevant factors include: species, strain, gender,
age, time of day, the immune challenge used and outcome
measured, and tissue differences in receptor expression.
With these contexts in mind, we now review GC and stress
effects on immunity and inflammation in the periphery. The
stress-induced thymic involution first noted by Selye was subse-
quently shown to be caused by CORT-induced, GR-mediated
apoptosis in immature T cells (Tarcic et al., 1998). Moreover,
chronic exposure to GCs (particularly synthetic GCs at supra-
physiological levels) inhibits both innate and adaptive immunity.
For example, chronic GC exposure reduces circulating leukocyte
counts and decreases the production of a large variety of proin-
flammatory cytokines including IL-1b and TNF-a (De Bosscher
et al., 2003).
The transcription factors nuclear factor (NF)-kB and activator
protein-1 (AP-1) play central roles in promoting inflammation,
and chronic GC signaling through the GR counters their actions
in multiple ways. GR signaling can increase the expression of the
inhibitor of NF-kB (IkB); however, blocking GR transcriptional
activity does not inhibit all of the anti-inflammatory properties
of GCs (Reichardt et al., 2001). GCs also decrease immune acti-
vation via protein-protein interactions between GR and NF-kB in
the nucleus (Figure 1) (De Bosscher et al., 2003).
During a stressful crisis, it seems logical that CORT sup-
presses nonessential activities like reproduction, growth, and
digestion. But an immunological challenge is itself a stressor,
and other stressful events can be accompanied by immunolog-
ical challenges; thus, decreased immune activity at such times
seems maladaptive. Insights into this puzzle came with
advances in methods for assaying CORT levels and immune
activation. Subsequent studies showed that prior to the release
of CORT, immune function is actually augmented early in the
stress response. This led to the theory that CORT secretion
during stress actually mediates recovery from this initial immune
activation (Munck et al., 1984). This theory predicts that if CORT
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excessive immune activation such as autoimmunity; indeed,
impaired CORT secretion is implicated in several autoimmune
disorders (Wick et al., 1993).
Basal GC Concentrations Are Required
for Immune Activation
The initial stress-induced increases in immune activity are
predominantly mediated by catecholamine release. Supporting
this conclusion, adrenoceptor antagonists inhibit stress-induced
increases in CNS cytokine production (Johnson et al., 2005).
CORT plays a role in this immune activation as well because
basal levels of CORT are required for the synthesis of E in the
adrenals (Wurtman and Axelrod, 1966) and for proper NE sig-
naling (Joels and de Kloet, 1989). This is an example of a
common situation in endocrinology, where basal levels of a
hormone exert ‘‘permissive’’ effects (i.e., are required for normal
functioning of other systems). One can readily appreciate the
adaptive benefits of immune activation early in the stress
response and recovery from such activation at later stages.
CORT Released during Acute Stress Stimulates
the Cellular Immune Response
Despite this teleology, acute stress still induces the high CORT
concentrations that lead to decreased blood leukocyte counts,
and this does not fit with the view that stress adaptively activates
the immune response. On closer examination, however, CORT-
induced decreases in blood leukocyte counts are not due to
apoptosis as long thought. Instead, acute stress directs these
cells to leave circulation and relocate to the tissues where they
might be needed, a redeployment from the ‘‘barracks’’ to the
‘‘battle stations’’ (McEwen et al., 1997). Acute physiological
exposure to CORT and GR agonists mimics this response
(Dhabhar et al., 1996). By contrast, chronic exposure to CORT
or synthetic GCs decreases the response, in line with the immu-
nosuppressive properties previously described (Dhabhar and
McEwen, 1997) (however, see Bowers et al., 2008 for a demon-
stration that, in some circumstances, chronic GC exposure can
augment cellular immunity).
The nature of the switch from acute-activating to chronic-
suppressive GC effects remains unknown. The fact that the
duration of GC exposure is so important to the outcome
suggests that the timing of the inflammatory challenge relative
to GC exposure is also important.
Acute CORT Exposure Primes a Subsequent
Inflammatory Response
If stress occurs prior to immune activation, it can have a
‘‘priming’’ effect that makes the subsequent response greater.
For example, acute stress 24 hr prior to lipopolysaccharide
(LPS) treatment augments LPS-induced increases in plasma
levels of IL-1b, TNF-a, and IL-6 (Johnson et al., 2002). By
contrast, acute stress post-LPS decreases the production of
these same cytokines (Goujon et al., 1995). Similarly, in cultured
macrophages, CORT treatment 24 or 12 hr prior to LPS
increases LPS-induced TNF-a, IL-6, and nitrite levels, while
CORT treatment at 6, 3, or 0 hr prior to LPS does not (Smyth
et al., 2004). In humans, plasma levels of TNF-a and IL-6 arehigher if cortisol is given 12 hr prior to, but not concurrent with,
LPS (Barber et al., 1993).
These studies provide exceptions to the traditional view that
GCs are uniformly anti-inflammatory. First, early in the stress
response, basal levels of CORT permit the immune-activating
actions of catecholamines. Second, stress-induced rises in
CORT levels facilitate immune cell mobilization to injured tissues.
Third, acute stress or CORT exposure can augment the
response to a subsequent inflammatory challenge. We now
consider how these novel GC effects apply to the CNS.
Stress and the Uninjured CNS
CORT has numerous effects in the uninjured brain, particularly in
regions with high levels of GR and MR (i.e., hippocampus and
cortex). For example, basal or acutely elevated CORT levels
increase synaptic plasticity and facilitate hippocampal-depen-
dent cognition. By contrast, chronically elevated CORT levels
impair synaptic plasticity and cognition, decrease neurogenesis
and spine density, and cause dendritic atrophy (McEwen and
Magarinos, 2001).
In the absence of injury, acute stress can activate inflamma-
tory mediators in the CNS. Acute stress increases NF-kB activity
(Madrigal et al., 2001), intracellular TNF-a-convertase activity,
extracellular TNF-a (Madrigal et al., 2002), and prostaglandin
E2 and COX-2 levels (Madrigal et al., 2003) in the cortex. At least
some of these stress effects are GC dependent and GR medi-
ated (Garcia-Bueno et al., 2008). Moreover, animals with higher
basal CORT levels have a greater accumulation of proinflamma-
tory mediators (Perez-Nievas et al., 2007).
Acute CORT Exposure Has Priming Effects
on Inflammation in the CNS
As in the periphery, the timing of GC exposure affects CNS
inflammatory responses. CORT given prior to LPS challenge
increases IL-1b and TNF-a expression in the hippocampus
(Frank et al., 2009). This does not depend on whether CORT is
administered 24 hr prior to LPS (which would allow CORT levels
to return to baseline by the time LPS is given) or 2 hr before
(which would be insufficient time). By contrast, CORT diminishes
the expression of these same cytokines when given 1 hr post
LPS. Microglia are important in this response because when
they are extracted from CORT pretreated rats and challenged
ex vivo with LPS, they upregulate MHCII and toll-like receptor-4
(TLR-4) and produce more IL-1b and TNF-a than microglia
extracted from control rats do (Frank et al., 2009).
Brain Regional Differences in GC Effects
There are also brain regional differences in how GCs modulate
the inflammatory response to LPS. For example, GR activation
during chronic stress increases LPS-induced NF-kB activation
and TNF-a, IL-1b, and iNOS expression in the hippocampus
and frontal cortex, but has opposite effects in the hypothalamus
(Munhoz et al., 2006). Moreover, TNF-a expression is increased
by chronic stress after intracortical LPS administration, also in a
GR-dependent manner (de Pablos et al., 2006). Supporting
these results, in the frontal cortex, GR signaling is essential for
chronic stress to increase LPS-induced activation of several
components of the MAPK signaling pathway involved inNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 35
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Cell: GCs may have cell-type-specific effects for
a number of reasons. Monocytes and granulo-
cytes, for example, differ greatly in their level of
GR expression and the variability in that expres-
sion between cells. In the CNS, GR is ubiquitously
expressed at relatively high levels in neurons,
astrocytes, and microglia, whereas MR expression
is restricted to the forebrain. Thus, in the CNS it is
not variation in receptor expression, but rather
cell-specific responses to GCs that might con-
tribute to functional differences. Signaling: LPS,
a stereotypical inflammatory challenge, binds to
TLR-4 at the plasma membrane, leading to activa-
tion of the MAPK and PI-3 kinase signaling path-
ways. MAPK signaling activates NF-kB and AP-1
and is antagonized by MKP-1 and AKT. GCs could
regulate inflammatory activation by inducing or
suppressing proteins involved in these pathways.
Transcription: We need a better understanding of
what genes are altered by GC signaling in different
contexts, and whether the changes are produced
by protein-protein interactions with other tran-
scription factors or direct activation of gene tran-
scription.activating NF-kB (de Pablos et al., 2006). While chronic GC
exposure can decrease GR protein levels, these studies used
GR inhibitors to demonstrate that GR signaling is required during
chronic stress to enhance inflammatory signaling in the fore-
brain.
The mechanisms leading to opposite responses in the hypo-
thalamus and forebrain are unknown. The mechanism cannot
be the same as what distinguishes between acute and chronic
GC exposure because all brain regions received an equivalent
duration of GC exposure. The mechanism also must be distinct
from what leads to GC priming because priming occurs in a
variety of regions including the cortex, hippocampus, hypothal-
amus, pituitary, and cerebellum (Johnson et al., 2002). We now
consider several mechanistic factors that could contribute to
these varied GC effects, beginning with those at the cellular level,
moving to intracellular signaling pathways, and ending in the
nucleus with gene transcription.
Putative Mechanisms underlying
the Inflammation-Enhancing Effects of GCs
GCs have cell-type-specific effects that could influence how
different tissues respond to their signaling. For example, even
after CORT enters the cell it is possible for it to be inactivated
by 11b-HSD (Figure 1), which can also vary in its expression.
The transcriptional effects of GCs may also be cell type specific,
as is the case with increased NF-kB signaling, which in neurons
is protective (Camandola and Mattson, 2007) and in microglia is
damaging (Kreutzberg, 1996). GC effects on microglia are partic-
ularly relevant, and indeed subacute stress induces GR-depen-
dent microglia proliferation (Nair and Bonneau, 2006) and prior
CORT exposure primes cytokine release from microglia ex vivo
(Frank et al., 2006).
Traditional endocrine and pharmacologic approaches are
limited by the fact that different cell types express variable
amounts of MR and GR, can be exposed to variable hormone
levels due to regulation, and even with similar receptor activation
might have completely different effects on neuronal survival36 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.during an injury (Figure 2). This can be addressed in vitro, or by
genetic approaches using cell-specific manipulations of regula-
tory proteins. We next consider some of these important
signaling molecules.
Proinflammatory signals activate NF-kB by binding to cell-
membrane receptors and activating intracellular signaling path-
ways (Figure 2). For example, LPS binds to TLR-4 and activates
the MAPK pathway, which activates NF-kB. The MAPK super-
family includes extracellular-regulated kinases (ERKs), c-Jun-
N-terminal kinases (JNKs), stress-activated protein kinases
(SAPK), and p38-MAPK (Karin, 1998). The activity of these
MAP kinases is antagonized by the PI-3 kinase/AKT pathway,
which inhibits TLR-4 signaling in macrophages (Zhang and Day-
nes, 2007).
GCs not only act genomically, but also via crosstalk with other
signaling pathways and transcription factors (De Bosscher et al.,
2003). Basal CORT levels induce SHIP1, which increases NF-kB
activation by inhibiting AKT (Zhang and Daynes, 2007). This
could explain the permissive effects of basal GCs. Higher levels
of CORT antagonize MAPK signaling by inducing expression of
MAPK phosphatase-1 (MKP-1), which reduces NF-kB activa-
tion. MKP-1 is a dual specificity phosphatase induced by cellular
stress, serum, and growth factors that dephosphorylates and
inactivates MAP kinases such as JNK, p38, and ERK1/2 (Clark
and Lasa, 2003). Acute GC exposure induces sustained expres-
sion of MKP-1 in a variety of cells including macrophages (Roger
et al., 2005). Proinflammatory stimuli such as LPS also induce
MKP-1 expression, creating a negative feedback loop that
downregulates production of TNF-a, IL-1b, and IL-6 (Zhao
et al., 2005). Reciprocally, MAPK (ERK and JNK) can decrease
GR nuclear transport and affinity to cofactors via phosphoryla-
tion (Rogatsky et al., 1998).
In addition to GR phosphorylation, the balance between
NF-kB and GR signaling is important in predicting GC actions.
The duration over which NF-kB remains active in the nucleus
may determine which genes it will activate (Hoffmann et al.,
2002). Normally, NF-kB induces the IkB family of genes to
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by inducing IkBa expression, but this is only one protein from
a family of NF-kB inhibitors.
The effects of different GC exposure conditions on GR, NF-kB,
and AP-1 transcriptional activation are minimally understood. In
one study, microarray profiling demonstrates that while DEX can
decrease human monocyte expression of many anti-inflamma-
tory genes, it simultaneously increases the expression of a
number of proinflammatory chemokines, complement proteins,
and cytokines (Galon et al., 2002).
An essential component of GR signaling is its interaction with
other transcription factors. As discussed, GR activation is
required for chronic-stress-augmented NF-kB activation, but it
is not known whether GR also affects AP-1. This role may not be
the same as that for NF-kB because different GR domains are
responsible for NF-kB and AP-1 interactions (Bladh et al., 2005).
Future research must therefore explore what changes in gene
transcription occur under different GC conditions. Chromatin
immunoprecipitation (ChIP) could be used to identify altered or
novel transcription factor binding targets. Combined with quan-
titative PCR, this could also shed light on the degree of target
induction. ChIP could also reveal a role for coactivators, core-
pressors, or chromatin-modifying enzymes in different GC expo-
sure contexts.
Functional Implications: GCs Endanger Injured Neurons
Until now we have primarily considered situations wheren inflam-
mation occurs in the absence of neuronal death (i.e., after LPS
administration). Numerous studies demonstrate that GC sig-
naling via GR makes neurons (most notably in the hippocampus)
less capable of surviving a variety of insults. For example,
subacute CORT treatment worsens CA1 hippocampal neuron
loss caused by global ischemia (Sapolsky and Pulsinelli, 1985)
and CA3 neuron loss caused by excitotoxins (Dinkel et al., 2003).
One mechanism to explain these endangering effects of CORT
is that the hormone decreases glucose transport into neurons
and glia in the hippocampus. As a result of this decreased energy
availability, following an excitotoxic insult, GC-treated neurons
are less capable of removing glutamate from the synapse,
extruding intracellular calcium, and quenching oxygen radicals
(Sapolsky, 1999).
GC-augmented inflammation may also contribute to this
endangerment. As evidence, prior acute stress worsens stroke
damage by increasing IL-1b levels in the postischemic cortex
(Caso et al., 2007). Moreover, subacute stress induces an
increase in TNF-a levels in the cortex, and blocking this increase
lessens stroke damage (Caso et al., 2006). Subacute CORT
treatment increases inflammatory cell recruitment and cytokine
production at an excitotoxic injury site (Dinkel et al., 2003).
Finally, chronic stress increases both neuronal death and astro-
cytic death in a GR-dependent manner after direct LPS injection
into the cortex (de Pablos et al., 2006). Importantly, in this study,
chronic stress occurred after the injury, but still increased LPS-
induced TNF-a expression and microglia activation.
These observations raise the question of whether GC-
augmented inflammation contributes to, or is solely a conse-
quence of, GC-augmented neuronal death. The former conclu-
sion is likely because GCs can augment LPS-induced CNSinflammation in the absence of neuronal death. Moreover, if
such augmentation adds to the ability of GCs to worsen neuronal
death, the augmentation must precede the death. This was seen
in one study where GCs increased inflammatory cell infiltration
prior to the emergence of neuronal death (Dinkel et al., 2003).
Conclusions
There are several points from this Perspective that we would like
to emphasize:
1. GCs, while renowned for their anti-inflammatory actions,
are not uniformly anti-inflammatory, including in the con-
text of CNS inflammation. Both GCs and stress (in a GC-
and GR-dependent manner) can augment aspects of
inflammation in the CNS, and these GC actions can exac-
erbate injury-induced neuronal death.
2. Whether GCs increase or decrease CNS inflammation
depends on the dose, timing, duration of GC exposure,
and the type of GC, since these steroids are a heteroge-
neous group of compounds.
3. While there is widespread use of GCs in clinical neurology
to control CNS inflammation in general and poststroke
edema in particular, such interventions are often ineffec-
tive and can even worsen clinical outcome (Gomes et al.,
2005). The findings reviewed in this Perspective further
support the notion that GCs should be used cautiously, if
at all, in many settings of clinical neurology.
4. Given these clinical implications, we would like to empha-
size the need for continued basic investigations to under-
stand the unexpected capacity of GCs to augment
aspects of CNS inflammation. Future research ought to
be directed at determining how GCs act on different cell
types and brain regions to produce such profoundly
different immunomodulatory outcomes. Insights will
require work at the systems, cellular, and molecular levels.
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